PUBLISHER: DelveInsight | PRODUCT CODE: 1173622
PUBLISHER: DelveInsight | PRODUCT CODE: 1173622
DelveInsight's " Complex Regional Pain Syndrome (CRPS) - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the CRPS, historical and forecasted epidemiology as well as the CRPS market trends in the United States, the EU4 and the UK and Japan.
The CRPS market report provides current treatment practices, emerging drugs, CRPS market share of the individual therapies, current and forecasted CRPS market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current CRPS treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032.
The DelveInsight's CRPS market report gives a thorough understanding of the disease. CRPS is a broad term describing excess and prolonged pain and inflammation that follows an injury to an arm or leg or any part of the body. CRPS is clinically characterized by sensory, autonomic, and motor disturbances; it can affect any part of the body, but occurs most often in the extremities. The wrist is most frequently affected after distal radial fractures. Complex regional pain syndrome can develop after different types of injuries, such as sprains and strains, surgeries, fractures, contusions, nerve lesions, stroke, etc.
CRPS has acute (recent, short-term) and chronic (lasting greater than six months) forms. Besides the increased perception of pain, other signs and symptoms that are seen with CRPS, particularly in its early stages are a warm, red, and swollen extremity on the affected side. There are two types of CRPS, Type I occurs after an illness or injury that did not directly damage a nerve in the affected area, and Type II follows a distinct nerve injury. Although the triggers vary, both types of CRPS have the same symptoms and go through the same three stages of the disease. CRPS used to be known as reflex sympathetic dystrophy (RSD) (Type I) and causalgia (Type II). Type I comprises about 90 percent of all cases of CRPS.
There are no objective diagnostic tests for CRPS. Since, its pathophysiologic basis of CRPS is not fully understood, mechanism-based diagnosis is not yet feasible. Therefore, the diagnosis of CRPS is based solely on clinical signs and symptoms. The actual diagnosis of CRPS is made solely based on history and physical examination to determine whether a patient meets CRPS diagnostic criteria (often called the Budapest criteria). Other than this, objective testing (thermography, triple-phase bone scan, quantitative sudomotor axon reflex test, or a trial sympathetic ganglion block) may be used to support a clinical diagnosis.
There is currently no cure or any medication that has been approved for CRPS specifically. The goal of currently available treatment is to manage the pain and to increase the mobility of the affected limbs. Effective treatment options in CRPS are limited and consist of both non-invasive and invasive therapies. Physical rehabilitation.
The CRPS epidemiology division provides insights about historical and current CRPS patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides a historical as well as forecasted CRPS epidemiology scenario in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2019 to 2032.
In 2021, the total prevalent case of CRPS was ~318,500 cases in the 7MM, which are expected to grow during the study period, i.e., 2019-2032.
The disease epidemiology covered in the report provides historical as well as forecasted CRPS epidemiology [segmented as Total Prevalent Cases of CRPS, Total Diagnosed Prevalent Cases of CRPS, Gender-specific Diagnosed Prevalent Cases of CRPS, Age-specific Diagnosed Prevalent Cases of CRPS, Type-specific Diagnosed Prevalent Cases of CRPS, Severity-Specific Diagnosed Prevalent Cases of CRPS, and Total treated cases of CRPS] in the 7MM covering the United States, EU4 countries and the United Kingdom, and Japan from 2019 to 2032.
The epidemiology segment also provides the CRPS epidemiology data and findings across the United States, the EU4 and the UK, and Japan.
The drug chapter segment of the CRPS report encloses the detailed analysis of CRPS marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the CRPS clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
The report provides the details of the emerging therapies under the late and mid-stage of development for CRPS treatment.
CRPS market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted CRPS market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.
This segment gives a thorough detail of the CRPS market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the CRPS market in 7MM is expected to witness a major change in the study period 2019-2032.
The CRPS market size in the 7MM is expected to change during the study period 2019-2032. The therapeutic market of CRPS in the seven major markets is expected to increase during the study period (2019-2032). In 2021, the total market size of CRPS was ~USD 58.4 million which is expected to rise during the study period (2019-2032).
The total market size of CRPS in the United States accounted for ~USD 50.9 million in 2021 which is expected to rise during the study period (2019-2032).
In the EU4 and the UK, the total market size of CRPS was ~USD 7 million in 2021, which is expected to rise during the study period (2019-2032).
In Japan, the total market size of CRPS was ~USD 0.5 million in 2021, which is expected to rise during the study period (2019-2032).
This section focuses on the rate of uptake of the potential drugs recently launched in the CRPS market or expected to get launched in the market during the study period 2019-2032. The analysis covers CRPS market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, and reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
The report provides insights into different therapeutic candidates in the Phase II, and Phase III stages. It also analyses CRPS key players involved in developing targeted therapeutics.
The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for CRPS emerging therapies.
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the CRPS domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or CRPS market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.
We perform Competitively and Market Intelligence analysis of the CRPS Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.